TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two deaths associated with counterfeit versions of investigational weight-loss drug retatrutide were reported to the FDA, according to CBS News. Separately, Novo Nordisk plans to stop selling the weight-loss injection Saxenda in early 2027 because of declining sales; the report does not connect the two developments.
Two deaths involving counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the U.S. Food and Drug Administration, according to CBS News. In a separate development, Novo Nordisk plans to discontinue its liraglutide injection Saxenda in early 2027, citing declining sales, according to a medical news roundup published October 13, 2026.
The report describes the retatrutide deaths as involving counterfeit products, not the authentic investigational medicine. It says the cases were reported to the FDA but provides no details about the people who died, where or when the deaths occurred, how the products were obtained, or what investigators have concluded about cause of death. The information is attributed to CBS News; the roundup does not provide an FDA statement or independent findings.
The separate Saxenda update concerns a commercial decision: Novo Nordisk said it plans to discontinue the weight-loss injection in early 2027 because sales have declined. The brief report does not identify which markets or product presentations are affected, give a specific final sales date, or describe arrangements for patients who currently use it. The two developments involve different medicines and should not be read as causally connected.
The roundup also notes that lawsuits continue to allege severe adverse events from GLP-1 receptor agonists, citing NPR. Those are allegations in ongoing litigation, not findings established by the brief. The report supplies no case details or legal outcomes. It also mentions research and policy developments, including World Health Organization guidance on obesity treatment in children and adolescents, but the central safety and availability updates are the counterfeit-product deaths and Saxenda’s planned withdrawal.
Risks From Counterfeit Weight-Loss Drugs
The reported deaths highlight a safety issue distinct from the evaluation of an approved medicine: a counterfeit product may not contain what its packaging claims, and the report offers no confirmed information about the substance, strength, contamination, or source involved in these cases. That lack of detail makes it impossible to draw conclusions about the specific cause of the deaths or the risks of authentic retatrutide.
For patients, the distinction matters. Retatrutide is described here as investigational, while Saxenda is an existing prescription product with a planned discontinuation. Counterfeit retatrutide reports do not establish that Saxenda is unsafe, and declining sales—not a safety reason—were given for Saxenda’s planned discontinuation. Patients should not treat these separate items as evidence of a shared problem across weight-loss medicines.
The planned Saxenda discontinuation may affect people who rely on the injection for weight management, but the report does not say what alternatives will be available or whether supply will change before early 2027. Patients using it will need more specific information from the manufacturer, regulators, pharmacies, and their clinicians as the timetable becomes clearer.
As an affiliate, we earn on qualifying purchases.
Two Separate Drug Developments
Retatrutide is identified in the report as an investigational weight-loss medication. The death reports concern counterfeit versions, and the roundup does not describe an FDA approval, an official recall, or a regulator’s determination about the cases. Reporting that deaths were submitted to the FDA is not the same as establishing that the authentic medicine caused them.
Saxenda is the brand name for injectable liraglutide used for weight management. The stated reason for Novo Nordisk’s plan to discontinue it is declining sales. The item appears among a collection of endocrinology news updates dated October 13, 2026, alongside reports on clinical studies, prescriptions, and other medical developments. This roundup format provides brief summaries rather than full investigation details.
The same report says new prescriptions for oral semaglutide marketed as Wegovy exceeded 100,000 within two months of its approval for weight management. That is a separate prescription update; it does not explain Saxenda’s planned discontinuation or establish that former Saxenda users will switch to oral semaglutide. The roundup gives no patient-level information about treatment changes.
“Two recent deaths tied to counterfeit versions of retatrutide were reported to the FDA.”
— CBS News, as cited in the October 13 medical news roundup
GLP-1 receptor agonist medications
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Details Behind the Death Reports
The source does not identify the people who died, the dates or locations, the products’ ingredients, or whether the cases have been independently investigated. It is also unclear whether the FDA has issued a public notice or taken any action related to the reported counterfeit products. No cause of death is established in the supplied account, and it does not say that authentic retatrutide was involved.
For Saxenda, the report does not specify the countries covered, the exact end date, whether all formulations will be affected, or how remaining supply and patient support will be handled. It also does not say whether Novo Nordisk’s plan is subject to regulatory steps or further announcements. The lawsuit item includes no names of cases, allegations in detail, or judgments, so its legal status cannot be assessed from this summary.
As an affiliate, we earn on qualifying purchases.
FDA and Saxenda Updates to Watch
Further information from the FDA or law enforcement could clarify the counterfeit products’ source, contents, and the circumstances of the deaths. Until such details are available, the report supports only the narrower point that two deaths involving counterfeit retatrutide were reported to the agency; it does not establish a cause or a finding about the investigational drug itself.
Novo Nordisk’s stated target is to discontinue Saxenda in early 2027. The company’s market-specific notices, regulator communications, and pharmacy guidance should clarify when sales end and what patients can expect. People currently prescribed Saxenda should ask their healthcare professional about their own treatment rather than stopping or changing medication based on a brief news roundup.
As an affiliate, we earn on qualifying purchases.
Key Questions
Were the reported deaths linked to authentic retatrutide?
The roundup says the deaths involved counterfeit versions of retatrutide. It does not report that authentic retatrutide caused the deaths.
Has the cause of the deaths been confirmed?
No cause is stated in the supplied report. Details about the cases, products, and any investigation findings are not provided.
Why is Novo Nordisk discontinuing Saxenda?
The roundup says Novo Nordisk cited declining sales. It does not describe the decision as a response to safety concerns.
When is Saxenda expected to be discontinued?
Novo Nordisk’s plan, as reported, is to discontinue the injection in early 2027. The report gives no exact date or market-by-market schedule.
Are the retatrutide reports and Saxenda decision connected?
The source presents them as separate developments: one concerns deaths reported in connection with counterfeit retatrutide, and the other is a commercial discontinuation plan for liraglutide.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
